United States Clinical Trials Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Clinical Trials Market Trends and Insights

Outsourcing Of Complex R&D Programs

The move toward outsourcing remains one of the clearest drivers of the United States clinical trials market. Sponsors are no longer sending only routine activities to outside partners, because they are also shifting regulatory work, safety support, site management, and post-approval obligations into broader service contracts. ACRO reported in March 2026 that member CROs conducted or participated in 7,634 studies involving 1.4 million patients in 2025 and supported 592 sponsor companies, which shows how much program volume is already flowing through external delivery networks.^{[1]Association of Clinical Research Organizations, “State of the Industry Report 2026,” ACRO, acrohealth.org} This matters because a broader outsourcing scope tends to lengthen relationships and raises switching costs once a provider is embedded across several programs. It also favors companies that can combine operational scale with therapeutic depth, which is why the United States clinical trials market increasingly rewards providers that can offer integrated clinical trial services instead of isolated tasks. Smaller generalist firms still compete, but growth is becoming harder where sponsors want fewer vendors and deeper accountability across full development programs.

Oncology And Rare-Disease Pipeline Expansion

Oncology remains the largest engine of study demand in the United States clinical trials market. IQVIA reported that oncology accounted for 38% of all Phase I to III industry-sponsored trial starts in 2025, and one-third of those starts involved novel modalities such as antibody-drug conjugates, radiopharmaceutical therapeutics, chimeric antigen receptor gene therapies, and multi-specific antibodies.^{[2]IQVIA Institute, “Global R&D Trends 2026 Report, Advancing Innovation in a Changing Landscape,” IQVIA, iqvia.com} These programs place heavier demands on site qualification, biomarker screening, cold chain handling, and long follow-up periods, which raises the need for specialized delivery teams. Rare-disease development adds another layer because patient pools are small and widely dispersed, making national outreach and flexible site coverage more important than traditional site-centric recruitment. AACR reported in 2026 that Phase I non-small cell lung cancer activity had consolidated at 223 US sites by 2024, which signals tighter access to high-performing oncology centers and reinforces the value of providers with established site relationships. As a result, the United States clinical trials market continues to favor CRO services that combine oncology scale with strong rare-disease recruitment models.

AI-Enabled Trial Design And Recruitment

AI is moving into everyday use across the United States clinical trials market rather than staying limited to pilot projects. ACRO found that 71% of member CROs used AI for study feasibility and site selection in 2025, while 64% used it for protocol optimization. That shift matters because feasibility, protocol design, and patient matching shape both study speed and study cost before enrollment even starts. A March 2026 paper in Nature Communications showed that AI-powered patient-to-trial matching systems can narrow the gap between eligible patients and enrolled cohorts, especially in orphan conditions where missed identification has been a long-standing problem. When providers combine these tools with operational delivery, they improve their chance of winning preferred-provider positions from sponsors managing broad portfolios of adaptive, basket, and biomarker-led studies. The practical effect is that the United States clinical trials market is starting to reward providers that use AI in both design and execution, not only in last-mile recruitment.

Hybrid And Decentralized Trial Adoption

Hybrid and decentralized models are becoming a normal part of how the United States clinical trials market is organized. The FDA final guidance issued in September 2024 gave sponsors and investigators a clearer framework for decentralized elements, including design, conduct, informed consent, digital health technology use, and investigator responsibilities under established compliance standards.^{[3]U.S. Food and Drug Administration, “Conducting Clinical Trials With Decentralized Elements, Guidance for Industry, Investigators, and Other Interested Parties,” Federal Register, govinfo.gov} That clarity reduced a major compliance barrier and made it easier for sponsors to move remote and community-based elements into routine trial planning. Frontiers in Medicine reported in 2025 that decentralized community-integrated research sites achieved randomization rates comparable with traditional sites in neurodegenerative disease work, which supports the case for broader use outside emergency settings. ICON and Advarra reinforced this direction in March 2026 when they announced a connected site network built to help research-naive sites participate with common technology and oversight. FDA guidance clarity and the long-term push for broader patient representation are both helping this model gain ground, even though execution still depends on site readiness and clean data capture.

Recruitment And Retention Shortfalls

Recruitment still acts as one of the main brakes on the United States clinical trials market. Frontiers in Medicine reported in 2025 that more than 80% of studies missed planned recruitment timelines, and the Association of Clinical Research Professionals reported in 2025 that 28% of sites still identified recruitment and retention as a top operating challenge. IQVIA also reported that median enrollment duration in 2025 exceeded 16 months, which shows how strongly this issue affects study delivery even in a large and mature research system. Retention is part of the same problem because losses after enrollment force sites and sponsors to over-recruit, reopen outreach, and add costs that were not planned at study start. The burden becomes even heavier when site teams are already stretched by multiple systems, staff turnover, and principal investigator shortages. For that reason, providers in the United States clinical trials market are putting more value on retention design, not just patient identification, and that is helping patient support services move closer to the core of clinical trial services.

Protocol Complexity And Cost Inflation

Protocol complexity continues to raise costs across the United States clinical trials market. Tufts Center for the Study of Drug Development data cited in 2024 showed that 76% of Phase I to IV protocols required at least one substantial amendment, and the same body of work placed median implementation cost at USD 141,000 for Phase II and USD 535,000 for Phase III protocols. The direct expense is only part of the issue, because each amendment also adds retraining, document revision, contracting work, and new room for site-level inconsistency. Advarra reported in 2026 that 45% of substantial amendments were avoidable through stronger feasibility and design work before activation, which underlines how much waste still enters studies early. At the same time, ACRP continued to highlight site pressure and investigator shortage as operating concerns in 2025, which means study teams often absorb complex revisions with limited extra capacity. This is why the United States clinical trials market is placing greater value on providers that can reduce avoidable complexity before a study opens, rather than simply managing costly changes after launch.

Segment Analysis

By Phase: Late-Stage Revenue Still Leads While Early-Phase Growth Accelerates

Phase III held 48.87% of phase revenue in 2025, which kept it as the largest phase segment in the United States clinical trials market. Large oncology, cardiovascular, and neurology programs supported that position because they required broad site networks, central lab coordination, and long monitoring cycles. The segment also benefited from resumed late-stage activity that had been deferred earlier, which raised contract value as more studies moved back into active enrollment windows. In practical terms, Phase III remains the part of the United States clinical trials market where sponsor budgets, monitoring effort, and operational complexity come together most clearly. That is why providers with strong site oversight and national delivery footprints still capture much of the largest contract pool.

Phase I is projected to expand at 7.36% CAGR through 2031, making it the fastest-growing phase in the United States clinical trials market. IQVIA reported that emerging biopharma companies generated 68% of all global Phase I starts in 2025, which supports the view that first-in-human activity is rising among sponsors that rely heavily on external partners. This pattern supports demand for CRO services because many of these sponsors do not maintain in-house units for healthy-volunteer work, dose escalation, or intensive safety management. It also supports clinical trial services that combine early-phase unit capacity with flexible outpatient access and tighter data turnaround. ICON reflected this direction in May 2026 by opening a new Clinical Research Unit in San Antonio and adding satellite outpatient clinics in Houston and Lawrence, which expanded early-phase capacity in the United States. 

By Study Design: Interventional Studies Dominate While Expanded Access Gains Importance

Interventional studies accounted for 69.83% of study design revenue in 2025 and therefore represented the largest share of the United States clinical trials market size within this segment. Their lead reflects the volume of randomized controlled work across oncology, immunology, and cardiovascular disease, where direct sponsor oversight and service intensity remain high. These studies generate heavier operational needs because they require active treatment assignment, site monitoring, endpoint collection, and protocol compliance across many settings. That structure keeps interventional work central to the United States clinical trials market even as more complementary evidence models develop. Observational programs remain important, but they usually create a different revenue profile because they are more closely linked to post-approval evidence, payer support, and real-world study design.

Expanded access is forecast to grow at 7.87% CAGR through 2031, which makes it the fastest-rising study design category in the United States clinical trials market. FDA guidance published in November 2025 continued to support public access pathways for investigational drugs used outside formal trial enrollment, which helps explain why this category is gaining more attention from sponsors. The segment also creates a more specialized operating need because adverse event reporting and oversight must run alongside the main development program without blurring responsibilities. That requirement opens room for providers that can coordinate safety, medical writing, and regulatory support within the same workflow. As a result, the United States clinical trials market is seeing more value placed on service providers that can handle expanded access execution with the same discipline applied to formal registration programs.

By Indication/Therapeutic Area: Oncology Leads the Revenue Base While Autoimmune Programs Expand Faster

Oncology captured 32.23% of indication revenue in 2025 and remained the largest therapeutic segment in the United States clinical trials market. IQVIA reported that oncology represented 38% of Phase I to III industry-sponsored trial starts in 2025, while ACRO showed that oncology made up 27% of member CRO study mix by count. That scale reflects both the depth of the cancer pipeline and the heavy service intensity attached to biomarker-led studies, novel modalities, and large late-stage programs. BioNTech added to that picture in May 2026 when it highlighted 13 ongoing pivotal trials across solid tumor indications, which points to sustained demand for complex oncology execution. Within the US clinical trials market, oncology remains the segment where provider experience, site access, and logistics depth are most visible to sponsors.

Autoimmune and inflammatory conditions are projected to grow at 6.97% CAGR through 2031, making them the fastest-growing therapeutic cluster in the United States clinical trials market. Growth here reflects a broader wave of targeted biologics and cell-based approaches moving into diseases such as lupus, rheumatoid arthritis, myositis, and multiple sclerosis, where study design and long follow-up remain demanding. Roche reinforced this momentum in April 2026 when its Phase III FENhance 1 and 2 studies met primary endpoints and showed fenebrutinib superiority over teriflunomide in relapsing multiple sclerosis. CNS, cardiovascular, and diabetes studies still provide an important revenue base, especially where confirmatory work and post-approval follow-up continue beyond registration. Even so, autoimmune growth is meaningful because it widens the demand base for providers beyond oncology and brings more specialized clinical trial services into the next phase of portfolio expansion.

By Sponsor: Pharmaceutical Companies Hold the Largest Share While Biotechnology Sponsors Grow Faster

Pharmaceutical companies held 63.74% of sponsor revenue in 2025 and therefore accounted for the largest sponsor base in the US clinical trials market share. Their lead reflects the large contract values attached to multi-regional Phase III programs, confirmatory studies, and long post-approval commitments in areas such as oncology and cardiovascular disease. Large pharmaceutical sponsors also keep an advantage because preferred-provider relationships give them steadier access to site networks, regulatory support, central lab capacity, and specialist delivery teams during busy enrollment periods. This makes the sponsor mix in the United States clinical trials market less about the number of sponsors and more about the size and complexity of the work that each sponsor group places with external providers. Medical device, academic, government, and nonprofit sponsors remain relevant, but they represent smaller and more distinct revenue pools with different timelines and contracting patterns.

Biotechnology companies are projected to expand at 7.46% CAGR through 2031, which makes them the fastest-growing sponsor segment in the US clinical trials market. IQVIA reported that emerging biopharma companies drove 68% of all Phase I trial starts in 2025, and that supports the view that early pipeline activity is shifting toward asset-light companies with limited internal infrastructure. This trend supports both CRO services and flexible clinical trial services because smaller sponsors often need outside partners for design, activation, recruitment, safety, and regulatory work at the same time. The opportunity is strong, but the operating model is different because providers must manage more sponsor relationships with smaller average contract values. That is why the US clinical trials market is increasingly split between large, high-value pharmaceutical programs and a faster-moving biotechnology pipeline that depends heavily on outside execution.

By Service Type: Monitoring Holds the Largest Base While Recruitment Services Expand Faster

Site management and monitoring accounted for 38.86% of service-type revenue in 2025, which made it the largest service segment in the United States clinical trials market. That lead reflects the demands of multi-site oncology and neurology studies, where monitoring intensity, query resolution, site contact, and compliance checks remain core delivery functions. Phase III volume also supports the segment because larger patient populations and broader endpoint structures raise visit frequency and oversight requirements. For many sponsors, this part of the US clinical trials market still defines the baseline value of outsourced execution because it connects protocol requirements to day-to-day study control. The segment remains difficult to displace even as more digital tools enter study management.

Patient recruitment and retention is projected to grow at 7.08% CAGR through 2031 and stands out as the fastest-growing service category in the United States clinical trials market. The growth rate reflects sponsor recognition that enrollment failure and patient loss are among the most common causes of delay, which makes dedicated support less optional than before. Protocol design and feasibility are also becoming more valuable because sponsors want to reduce avoidable amendments before a study opens, and Advarra reported in 2026 that 45% of substantial amendments were avoidable through better early planning. Pharmacovigilance is gaining attention as well, highlighted by Parexel's April 2026 acquisition of Vitrana to strengthen AI-enabled patient safety capabilities across the life cycle. Taken together, these shifts show that the US clinical trials market is slowly moving from a monitoring-heavy mix toward a broader service balance where recruitment, design, data, and safety carry more weight.

Geography Analysis

California leads the United States in active recruiting trial volume in 2026 with 1,246 trials, out of 7,755 active studies nationwide. New York, Massachusetts, Pennsylvania, and Maryland form the second major cluster with 758, 639, 606, and 537 active recruiting trials, which confirms that the United States clinical trials market remains concentrated around established coastal research corridors. This pattern reflects the density of academic hospitals, sponsor offices, FDA proximity in Maryland, and long-developed site networks. It also means patient access remains uneven, which matters as sponsors place more value on broader representation and wider geographic coverage in the US clinical trials market.

Texas and Florida stand out in the South with 818 and 857 active recruiting trials in 2026. Their position is supported by large urban populations, broad hospital systems, and rising interest in early-phase and community-linked site capacity. ICON added to this shift in May 2026 by opening a new San Antonio clinical research unit and launching satellite clinics in Houston and Lawrence. AACR reported in 2026 that Phase I non-small cell lung cancer activity had consolidated at 223 US sites by 2024, which shows why sponsors and providers are investing in new first-in-human access points outside the traditional coastal core. As site access tightens, broader state coverage is becoming a competitive advantage in the United States clinical trials market.

Ohio, Illinois, and Minnesota remain important Midwestern hubs because they combine strong academic infrastructure with more manageable activation timelines for Phase II and investigator-led work. The next shift is the spread of community-integrated research sites around large metro clinical research units, which can widen patient catchment without fully duplicating urban infrastructure. Frontiers in Medicine found in 2025 that decentralized community-integrated sites delivered randomization rates comparable with traditional models in neurodegenerative disease trials, which supports further expansion into suburban and semi-rural settings. States across the Dakotas, Wyoming, and other low-density areas still remain underserved, but FDA-compliant remote visit models are widening the future footprint of the United States clinical trials market.